Novartis has attained Tier 1 status in the 2026 CCLA Corporate Mental Health Benchmark, acknowledging its extensive commitment to workplace mental health, wellbeing, and employee support.
Read More
This independent evaluation assesses how major companies foster mental health, psychological safety, and access to care through their leadership, culture, governance, and employee experiences. Tier 1 represents the highest level of recognition from CCLA, indicating a strategic and holistic approach to employee support.
At Novartis, promoting mental health and wellbeing is seen as essential for cultivating an environment where employees can thrive and innovate. The company emphasizes that breakthrough ideas stem from the creativity and resilience of its workforce, and thus it continues to invest in mental health initiatives throughout the organization.
In 2026, Novartis introduced CareConnect, a global Employee Care Program that grants all employees access to confidential mental health and caregiving support, extending this benefit to eligible family members as well. The initiative aims to provide timely and personalized care.
Additionally, Novartis offers training for managers and educational programs for employees to increase awareness and capability while combating stigma associated with mental health issues. In 2026, over 2,000 managers participated in the mental health training program